What are the adverse effects of Abilify Maintena in adult patients with schizophrenia over a 12-month treatment period?

The primary adverse effects of 12-month Abilify Maintena treatment included mild-to-moderate symptoms (insomnia, headache, anxiety), weight gain in up to 25.7% of patients, neurological effects in 7.2-14.3%, and serious adverse events in 14.6% of cases.

Abstract

This systematic review examined the adverse effects of Abilify Maintena (aripiprazole once-monthly) in adult patients with schizophrenia over a 12-month treatment period. The review included 40 studies of various designs, including randomized controlled trials, observational studies, and systematic reviews, with sample sizes ranging from 15 to over 3,000 participants and study durations from 12 weeks to 6 years.

The most commonly reported adverse events were insomnia, headache, anxiety, akathisia, weight changes, and injection site pain. The frequency of these events varied across studies, with most being reported as mild to moderate in severity. Serious adverse events were relatively rare, with one study reporting serious adverse drug reactions in 14.6% of patients.

Metabolic effects, particularly weight changes and alterations in lipid profiles, were observed but generally less pronounced compared to some other antipsychotics. Clinically significant weight gain (≥7% increase) was reported in 11.2% to 25.7% of patients across different studies. Neurological effects, including akathisia and extrapyramidal symptoms, were reported at rates ranging from 7.2% to 14.3%.

Treatment discontinuation rates varied across studies, ranging from 14.28% to 41%, but were generally lower than those reported for oral antipsychotics. Common reasons for discontinuation included lack of efficacy, patient/caregiver choice, and adverse events. Notably, several studies reported good long-term persistence with Abilify Maintena, with one study finding that 69.6% of patients continued treatment over a four-year follow-up period.

Overall, the evidence suggests that Abilify Maintena has a generally favorable safety and tolerability profile in adult patients with schizophrenia over a 12-month treatment period. However, clinicians should monitor patients for a range of potential side effects, particularly weight changes, metabolic parameters, and neurological effects. The variability in study designs, populations, and reporting methods highlights the need for further long-term, head-to-head comparisons with other antipsychotics to fully elucidate the safety profile of Abilify Maintena.

Methods

We analyzed 40 sources from an initial pool of 490, using 7 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

• Population Age and Diagnosis: Adult patients (≥18 years) diagnosed with schizophrenia.
• Intervention: Treatment with Abilify Maintena.
• Study Duration: Greater than or equal to 12 months.
• Outcomes: Report adverse effects or safety outcomes.
• Study Design: Randomized controlled trial, observational study, systematic review, or meta-analysis.
• Sample Size: Inclusion of 10 or more patients.
• Study Type: Clinical study involving human subjects.

Characteristics of Included Studies

Study Design: Various designs including RCTs (8 studies), observational studies (12 studies), systematic reviews/meta-analyses (3 studies), and reviews (3 studies).

Safety and Adverse Effects

• Common Adverse Events: Weight gain, insomnia, akathisia, headache, anxiety, injection-site pain, tremor.
• Frequency: Varied widely across studies with clinically significant weight gain (≥7%) in 11.2% to 25.7% of patients.
• Severity: Most reported as mild to moderate; serious adverse drug reactions were noted in 14.6% of patients in one study.

Discontinuation Patterns

• Discontinuation Rates: Ranged from 14.28% to 41%.
• Reasons: Lack of efficacy, side effects, patient/caregiver choice.

Key Observations

• The adverse event profile is consistent with oral aripiprazole and highlights significant concerns around weight gain and metabolic effects.
• Monitoring for neurological effects, particularly akathisia and extrapyramidal symptoms, is critical.